Khandare Jayant J, Minko Tamara
Dept of Pharmaceutics, School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, NJ 08854-8020, USA.
Crit Rev Ther Drug Carrier Syst. 2006;23(5):401-35. doi: 10.1615/critrevtherdrugcarriersyst.v23.i5.20.
Antibodies and peptides play a variety of roles in cancer therapy: monoclonal antibodies (mAbs) and peptides are directly used in anticancer therapy and also as targeting moieties. More than 10 mAbs, either unconjugated or in immunoconjugate forms have been approved for use in oncology. Various peptides, tumor necrosis factors (TNFs), and cell surface-targeted peptides have been identified using phage-display libraries. In combination with standard chemotherapeutic agents, mAbs and peptides can significantly increase the toxicity of anticancer drugs to tumors and reduce their adverse side effects on normal tissues. The present review summarizes some major applications of antibodies and peptides in cancer therapy.
单克隆抗体(mAb)和肽直接用于抗癌治疗,也用作靶向部分。超过10种单克隆抗体,无论是未缀合的还是免疫缀合形式,已被批准用于肿瘤学。使用噬菌体展示文库已鉴定出各种肽、肿瘤坏死因子(TNF)和细胞表面靶向肽。与标准化疗药物联合使用时,单克隆抗体和肽可显著增加抗癌药物对肿瘤的毒性,并降低其对正常组织的不良副作用。本综述总结了抗体和肽在癌症治疗中的一些主要应用。